The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
TCT 2021 | Real-world treatment patterns & outcomes of functional high-risk myeloma
Ankit Kansagra, MD, UT Southwestern Medical Center, Dallas, TX, outlines the real-world treatment patterns and outcomes of patients with functional high-risk multiple myeloma. In this retrospective study, Dr Kansagra indicates that half of functional high-risk patients recieved stem cell transplantation in second line. This interview took place during the Transplantation & Cellular Therapy (TCT) 2021 Meetings.
